Title: |
Expert consensus on growth and development management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
Edition: |
Original |
Classification: |
Experts consensus |
Field: |
Administration |
Countries and regions: |
China |
Guidelines users: |
Endocrinologists and Paediatricians |
Evidence classification method: |
According to the evidence ranking schemes from Oxford Centre for Evidence-Based Medicine (OCEBM) , the evidence from the included studies will be divided into 6 levels of evidence (1a, 1b, 2a, 2b, 3, 4), and the strength of the recommendation will be divided into 3 levels according to the level of evidence: A (strong), B (moderate), and C (weak). |
Development unit: |
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
Registration time: |
2024-03-25 |
Registration number: |
PREPARE-2024CN460 |
Purpose of the guideline: |
To standardize the treatment and monitoring of growth and development in patients with 21-hydroxylase deficiency, and help specialists to accurately assess, standardize diagnosis and treatment, and avoid misunderstandings in the growth and development management of children with 21-hydroxylase deficiency. |